|
pharma market research - the original one-stop pharmaceutical information shop
PHARMA MARKET RESEARCH STUDIES
Long Term Care and Nursing Home Information Systems Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
Long Term Care and Nursing Home Information Systems Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
Stem Cell Markets
Point of Care Diagnostic Testing World Markets -
Portable and Transport Ventilator Market Shares Strategies, and Forecasts, Worldwide, 2010 to 2016
Portable and Transport Ventilator Market Shares Strategies, and Forecasts, Worldwide, 2010 to 2016
Major Pharmaceutical & Biotechnology Companies of the World 2010
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics -
|
|
|
News Article
Published: March 2005
Sector: Press Release
|
Fla., March 7 /PRNewswire/ -- WHAT: New studies presented this week, which look at the effects of ACTOS(R) (pioglitazone HCl) on in-stent restenosis, add to the growing body of information about ACTOS beyond blood sugar control. In-stent restenosis is a major set back in the long-term success after coronary stent implantation. It occurs when a blood vessel or heart valve re-closes after it has been treated using a stent (as following balloon angioplasty or valvuloplasty) with apparent success:
"Pioglitazone Reduces Neointima Formation After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Non-Diabetic Patients," by N. Marx et al.
"Pioglitazone Reduces Neointimal Hyperplasia After Coronary Stent Implantation in Nondiabetic Patients," by T. Katayama et al.
"Inhibitory Effect of Low Dose Pioglitazone on the Development of In-Stent Restenosis in Patients With Type 2 Diabetes Mellitus," by J. Yokayama et al.
WHY: Cardiovascular disease and diabetes are converging epidemics: cardiovascular disease is the leading cause of premature death among people with diabetes. Studies have shown ACTOS has a positive effect on certain markers of cardiovascular risk, such as diabetic dyslipidemia, atherogenic lipids and c-reactive protein. One study in particular found that ACTOS has an overall positive effect on dyslipidemia (low HDL-cholesterol, high triglycerides, high levels of small, dense LDL-cholesterol) in patients with type 2 diabetes, as compared to rosiglitazone.
ACTOS is an important and effective treatment option for people with type 2 diabetes as an adjunct to diet and exercise. Since the introduction of ACTOS in August 1999, more than 40 million prescriptions have been written, covering more than 5.5 million patients and 2.9 million patient years. Takeda Pharmaceuticals North America, dedicated to patient health and safety, has offered the continued and uninterrupted supply of ACTOS in the United States for more than five years.
ACTOS is not for everyone. ACTOS may cause fluid retention which may lead to or exacerbate heart failure. ACTOS has also been associated with edema and in rare instances hepatic failure has been reported.
This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.
For full details, please email keithw@cmsinfo.com
|